Core Viewpoint - Charlotte's Web Holdings, Inc. has announced a significant transaction with British American Tobacco (BAT) involving the conversion of a C$75.3 million (approximately US$54 million) convertible debenture into common shares and an additional US$10 million equity investment to strengthen its balance sheet and support operational priorities [1][4][10]. Transaction Overview - The transaction consists of two main components: the conversion of the outstanding debenture into common shares at a conversion price of C$0.94 (approximately US$0.67) and a concurrent private placement of US$10 million [1][9]. - The total equity commitment from BAT amounts to approximately US$75 million, resulting in the issuance of about 110 million common shares to BAT [1][10]. Financial Impact - Following the transaction, approximately US$65 million of total debt will be eliminated from Charlotte's Web's balance sheet, ceasing interest accrual on the debenture and enhancing liquidity for near-term operations [2][4]. - The conversion simplifies the company's capital structure and avoids approximately US$12 million in future interest payments [4][6]. Strategic Initiatives - The company is preparing for participation in the Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program, which requires internal investment for optimal execution [3][6]. - BAT's investment reinforces Charlotte's Web's strategic plans to expand its medical channel and participate in the CMMI program, subject to regulatory approvals [6][9]. Shareholder Approval - Shareholder approval for the transaction will be sought at the annual general and special meeting scheduled for around May 28, 2026 [7][13]. - The transaction is subject to TSX approval and is expected to close on or about the same date [14]. Investor Rights Agreement - Upon closing, an amended and restated investor rights agreement will be established, allowing BAT to nominate directors proportional to its equity ownership and imposing certain restrictions on equity issuances and indebtedness [12]. Ownership Structure Post-Transaction - After the transaction, BAT will hold approximately 40% of the issued and outstanding common shares of Charlotte's Web, based on the expected total shares outstanding post-transaction [10][18].

Financial Data and Key Metrics Changes - The company reported a record Q2 net revenue of $218 million, with an adjusted EBITDA of $8.4 million and a reported EPS loss of $0.02, reflecting a significant improvement in performance metrics [4][22]. - The net loss for the quarter was $43.5 million, a 49% improvement year-over-year compared to $85.3 million, with cash flow used in operations down to $8.5 million from $40.7 million last year [27][28]. Business Line Data and Key Metrics Changes - Cannabis net revenue increased to $67.5 million, driven by a 36% increase in international cannabis revenue and a 6% increase in Canadian adult use cannabis [22][23]. - Beverage revenue totaled $50.1 million, impacted by headwinds in the craft beer segment, while distribution revenue grew by 26% year-over-year to $85.3 million [11][25]. - Wellness revenue remained flat at $14.6 million, with challenges in the club retail channel being addressed [20][25]. Market Data and Key Metrics Changes - International cannabis revenue reached $20 million, marking a 51% sequential growth and a 36% year-over-year increase [9][22]. - The Canadian adult use medical sales channel net of excise tax grew to $46 million, with recreational cannabis growing 6% in the quarter [12][22]. Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and liquidity to capitalize on growth opportunities in the evolving global cannabis regulatory environment, particularly in the U.S. [5][29]. - Tilray is focused on expanding its pharmacy reach in Germany and tripling its medical cannabis distribution footprint in fiscal 2026 [10][11]. - The company is also pursuing international growth by expanding its beverage business into new markets, including the U.K., Middle East, and Africa [19][20]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the second half of fiscal 2026 and beyond, citing a diversified platform and improving fundamentals [21][29]. - The company is prepared for potential regulatory changes in the U.S. regarding cannabis rescheduling, which could enhance its market position [7][87]. Other Important Information - The company ended the quarter with approximately $292 million in cash and marketable securities, with a net cash position exceeding debt by almost $30 million [5][28]. - The company is committed to investing in research and clinical trials to develop approved cannabis drugs for various medical conditions [85][86]. Q&A Session Summary Question: What can the industry do to improve the regulatory outcome regarding the intoxicating hemp ban? - Management is working with legislators to extend the deadline or modify regulations to allow for a regulated amount of milligrams to be sold nationally [32][34]. Question: Can you quantify how much supply was held back from the Canadian wholesale market? - Approximately $5 million worth of supply was held back, which will be redeployed into higher-margin international markets [38][39]. Question: How much of the Canadian adult use cannabis growth was volume versus price mix? - The growth was primarily driven by demand and new distribution, with a slight market share gain [44][46]. Question: What are the expectations for growth within the Canadian market? - Management expects mid- to high single-digit growth in the Canadian market, focusing on premium products and new product launches [58][60]. Question: Can you provide more color on the CC Pharma business and its distribution reach? - The company has modernized CC Pharma and is focused on expanding its pharmacy reach, with plans to sell more medical cannabis through its sales organization [66][68]. Question: What is the long-term outlook for the beverage business? - Management remains confident in the beverage business, emphasizing the importance of integration and the potential for future opportunities in cannabis-infused drinks [76][77].

Financial Data and Key Metrics Changes - The company reported a record Q2 net revenue of $218 million, with an adjusted EBITDA of $8.4 million and a reported EPS loss of $0.02, reflecting a significant improvement in performance metrics [4][22]. - The net loss for the quarter was $43.5 million, a 49% improvement year-over-year compared to $85.3 million, with cash flow used in operations reduced to $8.5 million from $40.7 million last year [27][28]. Business Line Data and Key Metrics Changes - Cannabis revenue increased to $68 million, with international cannabis revenue growing 36% year-over-year and 51% sequentially to $20 million [9][22]. - Beverage revenue totaled $50 million, impacted by headwinds in the craft beer segment, while distribution revenue grew by 26% year-over-year to $85 million [11][23]. - Wellness revenue remained flat at $14.6 million, driven by innovation in product offerings [20][24]. Market Data and Key Metrics Changes - The Canadian adult-use cannabis sales channel net of excise tax grew to $46 million, with recreational cannabis growing 6% in the quarter [12][22]. - The international cannabis market, particularly in Europe, is seen as a significant growth opportunity, with expectations for continued expansion in Germany, the UK, and Poland [10][39]. Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and liquidity to capitalize on regulatory changes in the cannabis industry, particularly in the U.S. [5][29]. - The strategic focus includes enhancing operational efficiency in the beverage segment and expanding pharmacy reach in Germany through Tilray Pharma [11][18]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the second half of fiscal 2026, citing a diversified platform and improving fundamentals [21][29]. - The company is preparing for potential regulatory changes in the U.S. that could significantly impact the cannabis market, particularly with the rescheduling of cannabis [6][54]. Other Important Information - The company operates more than 40 brands in over 20 countries and is a leader in the cannabis market, with a strong position in both the Canadian and international markets [5][6]. - The company has a robust cash position of approximately $292 million, providing flexibility for strategic opportunities [5][28]. Q&A Session Summary Question: What can the industry do to improve the regulatory outcome regarding the intoxicating hemp ban? - Management is working with legislators to extend the deadline or modify regulations to allow for a regulated amount of milligrams to be sold nationally [30][31]. Question: Can you quantify how much supply was held back from the Canadian market? - Approximately $5 million worth of supply was held back to redeploy into higher-margin international markets [32]. Question: What drove the substantial increase in distribution sales? - The increase was driven by new distribution channels and competitive pricing, with a focus on high-margin SKUs [34][36]. Question: What are the expectations for growth within the Canadian market? - Management expects mid- to high single-digit growth in the Canadian market, supported by new product launches and strong demand [40][41]. Question: Can you provide more color on the CC Pharma business and its distribution reach? - The company aims to triple its distribution reach in Germany, leveraging its sales organization to sell more medical cannabis [44][46]. Question: What is the long-term outlook for the beverage business? - Management remains confident in the beverage business, emphasizing the importance of integration and the potential for future growth, particularly with cannabis-infused drinks [51][53].